Long-term persistence of primary genotypic resistance after HIV-1 seroconversion

被引：99

作者：

Pao, D

Andrady, U

Clarke, J

Dean, G

Drake, S

Fisher, M

Green, T

Kumar, S

Murphy, M

Tang, A

Taylor, S

White, D

Underhill, G

Pillay, D

Cane, P ^{[1
]}

机构：

[1] Univ Birmingham, Sch Med, Div Immun & Infect, Antiviral Susceptibil Reference Unit,Hlth Protec, Birmingham B15 2TT, W Midlands, England

[2] Royal Sussex Cty Hosp, Brighton BN2 5BE, E Sussex, England

[3] Ys Byty Gwynedd, Bangor, Gwynedd, Wales

[4] Leeds Gen Infirm, Leeds, W Yorkshire, England

[5] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England

[6] Pinderfields Gen Hosp, Wakefield, England

[7] Queen Elizabeth Hosp, Kings Lynn, England

[8] St Bartholomews Hosp, London, England

[9] Royal Berkshire Hosp, Reading RG1 5AN, Berks, England

[10] Portsmouth Hosp, Natl Hlth Serv Trust, Portsmouth, Hants, England

[11] UCL, London, England

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2004年 / 37卷 / 05期

关键词：

HIV-1; primary drug resistance; persistence of mutations;

D O I：

10.1097/00126334-200412150-00006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.

引用

页码：1570 / 1573

页数：4